MEDPAL AI is trading at £4.40 (+5.26%) amid healthcare-sector strength.
- No fresh company-specific announcement was identified on August 12, 2026.
- The latest listed RNS, dated August 11, concerned UK authorisation of Eli Lilly’s once-daily GLP-1 pill; available coverage does not establish it as the direct catalyst.
- Recent momentum also follows MedPal AI’s August 4 record July trading update, although that catalyst is not new.